HOX11 gene overexpression is associated with recurrence of acute B lymphoblastic leukaemia.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
This research aimed to elucidate the association of Homeo Box 11 (HOX11) gene overexpression with refractory acute B-cell lymphoblastic leukaemia (B-ALL). In this investigation, 209 patients with B-ALL, who were treated in Guangdong Province between 2019 and 2024, were included. At the initial diagnosis, the RNA was obtained from bone marrow for genetic testing via Real-time Quantitative Polymerase Chain Reaction (RQ-PCR). Furthermore, the clinical data were acquired and the association of HOX11 with these clinical features and gene alterations was analysed. Finally, the relationship between gene alterations and progression-free survival (PFS) was analysed. Of the 209 B-ALL patients, 42 (20.1%) had recurrent disease. Twenty-six (12.4%) had HOX11 overexpression, of which 10 had recurrent disease. Furthermore, the HOX11 overexpression patients indicated TP53 concomitant of 23.07%, whereas the HOX11 low-expression patients showed TP53 concomitant of 8.7% (p < 0.05). Logistic regression indicated lower WBC counts and higher recurrence rates in the HOX11 overexpression group (p < 0.05). PFS analysis indicated that the HOX11 overexpression group and KMT2A::AFF1 group were associated with higher disease recurrence (p < 0.05). Cox regression analysis showed that HOX11 was an independent risk factor affecting PFS (p = 0.041). These findings are the first to demonstrate an association between HOX11 overexpression and recurrent B-ALL.